patients (Log-rank P < 0Á001). Multivariate analysis only showed MYD88 mutation status (P < 0Á001) as a significant determinant for overall survival. Diffuse large B-cell lymphoma (DLBCL) was diagnosed in 7 (15Á2%) and 2 (0Á76%) of MYD88 WT and MYD88 MUT patients, respectively (Odds ratio 23Á3; 95% CI 4Á2-233Á8; P < 0Á001). Overall survival was shorter among MYD88 WT patients with an associated DLBCL event (Log-rank P = 0Á08). The findings show that among suspected MYD88
Summary
MYD88 mutations are present in 95% of Waldenstrom Macroglobulinaemia (WM) patients, and support diagnostic discrimination from other IgM-secreting B-cell malignancies. Diagnostic discrimination can be difficult among suspected wild-type MYD88 ( patients (Log-rank P < 0Á001). Multivariate analysis only showed MYD88 mutation status (P < 0Á001) as a significant determinant for overall survival. Diffuse large B-cell lymphoma (DLBCL) was diagnosed in 7 (15Á2%) and 2 (0Á76%) of MYD88 WT and MYD88 MUT patients, respectively (Odds ratio 23Á3; 95% CI 4Á2-233Á8; P < 0Á001). Overall survival was shorter among MYD88 WT patients with an associated DLBCL event (Log-rank P = 0Á08). The findings show that among suspected MYD88
WT WM cases, an alternative clinicopathological diagnosis is common and can impact clinical care. WM patients with MYD88 WT disease have a high incidence of associated DLBCL events and significantly shorter survival versus those with MYD88 MUT disease.
Keywords: Waldenstr€ om Macroglobulinaemia, IgM myeloma, transformation, MYD88, overall survival.
Next generation sequencing has identified somatic MYD88 mutations in Waldenstrom Macroglobulinaemia (WM) that include L265P and non-L265P variants (Treon et al, 2012 (Treon et al, , 2015 . Allele-specific polymerase chain reaction (AS-PCR) assays and Sanger sequencing methods have determined that MYD88 mutations are present in 93-97% of WM patients (Jim enez et al, 2013; Poulain et al, 2013; Varettoni et al, 2013; Xu et al, 2013) . MYD88 mutations are activating, and provide growth and survival support through Bruton tyrosine kinase (BTK), Interleukin 1 receptor associated kinases 1 and 4 (IRAK1/IRAK4) and haematopoietic cell kinase (HCK) in WM cells (Treon et al, 2014 (Treon et al, , 2015 . CXCR4 mutations are also uncommon in MYD88 WT patients, but may be found in up to 40% of MYD88 MUT cases 
Patients and methods
Sixty-four patients with suspected MYD88 WT WM were identified. All patients had a monoclonal IgM protein, and morphological and histopathological findings on a bone marrow (BM) biopsy that were suspicious for lymphoplasmacytic lymphoma. AS-PCR testing for MYD88 L265P mutation, and investigation for non-L265P MYD88 mutations in negative cases by Sanger sequencing was performed in all these cases to confirm MYD88 WT status utilizing CD19-selected and unselected BM mononuclear cells . A systematic review of clinical, pathological, and laboratory studies was undertaken for all MYD88 WT cases, and further studies were obtained as warranted, which included additional immunohistochemistry, skeletal and computed tomography imaging, and CXCR4 mutation determination . WHO and WM consensus guidelines (Owen et al, 2003; Swerdlow et al, 2008) were used to establish definitive diagnosis. Data sets were evaluated by analysis of variance and nonparametric comparisons made by the Fisher's exact probability test. The survival from WM diagnosis, defined as the time between WM diagnosis to last follow-up or death, and the time from WM diagnosis to transformation to an aggressive lymphoma were estimated using the Kaplan-Meier method. Survival curves were compared using the log-rank test. For the survival estimates in WM patients who did or did not transform to an aggressive lymphoma, we used the SimonMakuch method, and the Mantel-Byar test for comparison (stsplit in STATA). Follow-up time was estimated by reverse censoring. Univariate and multivariate survival analyses were performed using Cox proportional-hazard regression models. The outcome of interest is reported as hazard ratio (HR) with 95% confidence interval (CI). A P value <0Á05 was deemed to be significant. All calculations and graphs were obtained using STATA/SE 13.1 (StataCorp, College Station, TX). serum IgM for these patients was 29Á8 (range 1Á6-90 g/l), and haemoglobin was 110 (range 40-1Á5 g/l). Sixteen (35%) and 13 (28%) had adenopathy and splenomegaly, respectively. Principal reasons for their diagnosis included anaemia (n = 23; 50%), and/or other cytopenias (n = 6; 13%), peripheral neuropathy (n = 8; 13%), adenopathy (n = 5; 8%), hyperviscosity (n = 3; 5%) and renal failure (n = 3; 5%). Twelve (26%) patients had a familial history for B-cell malignancies. Four (8Á7%) patients had frameshift CXCR4 mutations. At a median follow-up of 5Á0 (range 0Á8-17Á9 years), 31 (67%) patients required therapy. Notably, 7 (15%) MYD88 WT patients were also diagnosed with diffuse patients. Adenopathy and splenomegaly were present in 4 (67%) and 2 (33%) patients. None had a familial history, and no CXCR4 mutations were observed. Only one patient had noteworthy cytogenetics that showed a t(3;6)(q13.3;p25) translocation. Hepatitis C virus testing was unremarkable. Principal reasons that led to diagnosis included anaemia (n = 4; 67%) and/or other cytopenias (n = 1; 17%) and peripheral neuropathy (N = 1; 17%). With a median followup of 3Á8 (range 1Á3-5Á2 years), four (67%) required therapy, and are alive. No DLBCL events occurred in these patients.
Results
For 3 patients, the findings favoured a diagnosis of IgM monoclonal gammopathy of undetermined significance (MGUS) with plasma cell infiltration. The median BM involvement for these patients was 5% (range 5-8%) with flow cytometric analysis demonstrating a clonal plasma cell population. The median serum IgM level for these patients was 18Á46 (range 12Á62-23Á9 g/l), and did not differ significantly versus MYD88
WT WM patients. None had a familial history, and none had CXCR4 mutations. In two patients, the diagnosis was incidental to elevated total protein. In one patient, IgM MGUS was diagnosed for work-up of fatigue. With a median follow-up of 2Á5 (range 2Á5-3Á2 years), none have progressed or received treatment, and all remain alive. No DLBCL events were observed. Lastly, in one patient, the findings favoured the diagnosis of CLL while another patient had intravascular DLBCL, with respective serum IgM levels of 18Á22 and 3Á55 g/l. The BM disease burden was 5% in both patients. None had a familial history or CXCR4 mutations. The CLL patient remains alive without treatment and a DLBCL event, while the patient with DLBCL required therapy and remains alive. We next sought to address the impact of MYD88 mutation status on overall survival in WM patients. Survival outcome was compared to 262 patients with MYD88
MUT disease who were diagnosed over the same time-period. The median follow-up for all patients was 74Á7 (0Á5-324Á9 months), and was similar for MYD88 WT and MYD88 MUT WM patients (64Á1 vs. 73Á7 months, respectively; P = 0Á71). Patient characteristics are shown in Table II . Among 262 MYD88 MUT patients, 261 had L265P and 1 had S243N MYD88 mutation; 101 (38Á5%) were also CXCR4 mutated. During the followup period, there were 11 (23Á9%) deaths for the MYD88 WT versus 15 (5Á7%) deaths among MYD88 MUT patients (P = 0Á003). Figure 1A shows overall survival based on MYD88 and CXCR4 mutation status from time of diagnosis for all patients. The estimated 10-year survival was 73% (95% CI 52-86%) and 90% (95% CI 82-95%) for MYD88 WT and MYD88 MUT patients, respectively (Log-rank P < 0Á001), and did not differ within MYD88 MUT patients by CXCR4 mutation status (Log-rank P = 0Á69). Multivariate analyses that included age, gender, serum IgM, haemoglobin, BM disease involvement, serum b 2 -microglobulin, MYD88 and CXCR4 mutation status showed that MYD88 mutation status alone was a significant determinant for overall survival. The Table III . Transformation to DLBCL occurred during the follow-up period in 7 (15Á2%) and 2 (0Á76%) MYD88
WT and MYD88
MUT patients, respectively. The incidence of transformation to DLBCL at 10 and 20 years was 1% (95% CI 0Á1-5%) and 8% (1-39%) in MYD88 MUT patients versus 20% (95% CI 8-45%) and 29% (95% CI 12-58%) in MYD88 WT patients (HR for DLBCL transformation 19Á8, 95% CI 4Á08-95Á8, P < 0Á001; Fig 1B) . Overall survival estimates at 10 and 20 years for WM patients who did not transform to DLBCL were 88% (95% CI 81-93%) and 66% (95% CI 40-83%), respectively, and for WM patients who transformed to DLBCL were 63% (95% CI 23-86%) and 42% (7-75%), respectively (Mantel-Byar P = 0Á003; Fig 1C) .
Discussion
The above findings suggest that while most patients with suspected MYD88 WT WM disease fulfil WHO and consensus criteria for the diagnosis of WM, up to 30% had an alternative diagnosis. Surprising was the high number of IgM MM cases, many of which had clonal B-cells and plasma cells. These patients had a predominant plasma cell component by histological examination, and exhibited high serum IgM levels (median 83Á75 g/l) that distinguished them from MYD88 WT WM patients (median 29Á8 g/l; P = 0Á016). FISH studies showed that 86% of IgM MM patients carried chromosome 14 translocations, consistent with earlier reports (Avet-Loiseau et al, 2003a; Willenbacher et al, 2013) . High serum IgM levels and a lymphoplasmacytic-like BM infiltrate in IgM MM was also observed by Avet-Loiseau et al (2003b All MZL patients were female, consistent with prior reporting for female prevalence for MZL (Arcaini et al, 2011) . Subtle differences in BM morphology, including a more predominant paratrabecular and nodular pattern of disease involvement with small to medium size lymphocytes and few plasma cells, helped discriminate these patients (Arcaini et al, 2011; Kyrtsonis et al, 2011; Bassarova et al, 2015) . Principal diagnostic complaints, findings from the physical examination, imaging and laboratory studies, including serum IgM levels, flow cytometry and cytogenetics, did not provide much separation between MYD88 WT WM, and MZL, highlighting the need for investigation of the genomic basis of MYD88 WT WM, and development of molecular markers to discriminate this entity from MZL and other related diseases. An important finding in this study was also the high incidence of associated DLBCL cases in MYD88
WT WM patients.
It is unclear whether these events represented true histological transformation or secondary primary B-cell malignancies, but they contributed to 4 of the 11 (36%) deaths observed in the MYD88 WT WM patients. In contrast, none of the other
MYD88
WT patient cohorts had an associated DLBCL diagnosis. Transformation is uncommon in WM patients, particularly among those na€ ıve to nucleoside analogues, with an estimated incidence rate of <5% (Leleu et al, 2009; Castillo et al, 2016 
B 2 M, b 2 -macroglobulin; CI, confidence interval; HR, hazard ratio. many MYD88 WT WM cases, that may also account for the higher risk of death previously reported by us (Treon et al, 2014) , and that was also observed in this greatly expanded study. As before, we saw no impact of CXCR4 mutation status on overall survival in MYD88 MUT patients. Among
WT patients who transformed, overall survival was shorter in this study. Significantly shorter overall survival (9 years vs. 16 years) was also observed previously in transformed WM patients . The median overall survival for all patient populations, including MYD88
WT WM patients, was not reached in this study ( Fig 1A) . Longer follow-up will invariably be required to better clarify the relative risk of death associated with MYD88 mutation status in WM patients, and among IgM secreting B-cell malignancies. 
